Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in New York

If you’re a psychiatrist or PMHNP considering offering weight management services—or just curious whether you can legally prescribe GLP-1s or phentermine to patients via telehealth—you’re asking the right questions. The short answer: Yes, psychiatrists can prescribe weight-loss medications, including via telehealth, but the rules vary dramatically by state and medication type.

Here’s what you actually need to know to stay compliant and avoid regulatory headaches in 2026.

The Federal Picture: DEA Rules for Telehealth Prescribing

Let’s start with the elephant in the room: controlled substances. Many weight-loss medications—like phentermine (Adipex-P)—are Schedule IV controlled substances. Under the Ryan Haight Act, the DEA normally requires an in-person medical evaluation before prescribing any controlled substance via telemedicine.

But here’s where we are in 2026: The DEA and HHS have extended COVID-era telehealth flexibilities through December 31, 2026. This means you can currently prescribe controlled substances—including phentermine—via telehealth to new patients without an initial in-person visit, as long as you conduct a proper video evaluation and meet the standard of care.

However, this is explicitly temporary. The DEA is developing permanent rules that will likely require either special telemedicine registrations or impose limits (like initial 30-day supplies for certain medications). Some proposed rules suggest psychiatrists might get carve-outs for ADHD stimulants, but details are still being finalized through public comment periods.

The key takeaway: Don’t build your entire practice model around current flexibilities. The regulatory landscape will shift, probably by 2027.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What About GLP-1 Medications?

Here’s some good news: GLP-1 agonists like semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are NOT controlled substances. They’re not subject to DEA’s in-person exam requirements at all.

This means you can prescribe them via telehealth in most states as long as you:

• Conduct an appropriate medical evaluation (typically via video)
• Document the patient’s BMI and weight-loss treatment plan
• Follow your state’s telehealth and prescribing standards

The regulatory scrutiny on GLP-1s comes from state medical boards and standard-of-care expectations, not from federal controlled substance laws.

State-Specific Rules That Actually Matter

Federal rules are just the starting point. States can—and do—impose stricter requirements. Here’s what you need to know for the major markets:

New York: The Strictest Approach

New York currently requires at least one in-person medical evaluation before prescribing any controlled substance to a patient. Period. The only exceptions are narrow: if another NY provider saw the patient in person within the last 12 months and referred them, if you’re covering for a colleague, or in emergencies (max 5-day supply for existing patients).

What this means for weight loss: You cannot start a New York patient on phentermine via telehealth alone. You’d need either an in-person initial visit or a hybrid model where another provider conducts the physical exam.

For GLP-1s (non-controlled), you’re fine with telehealth-only in NY—but you still need to meet professional standards and document a thorough evaluation.

Florida: Clear Rules, Specific Requirements

Florida is actually more permissive for telehealth, with one important carve-out: you cannot prescribe Schedule II controlled substances (like Adderall) via telehealth EXCEPT for psychiatric treatment, inpatient care, hospice, or nursing home residents.

Since phentermine is Schedule IV, you can prescribe it via telehealth in Florida. But here’s what Florida’s Board of Medicine requires for ANY obesity treatment:

• Patient must have BMI ≥30 (or ≥27 with comorbidities)
• Document an appropriate initial evaluation (can be via telehealth)
• Obtain written informed consent explaining risks and benefits
• Re-evaluate the patient at least every 3 months if continuing weight-loss medications
• Provide each patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’

Florida also has specific advertising restrictions—you cannot guarantee specific weight loss results or make misleading claims about credentials.

California: Progressive but Regulated

California allows telehealth prescribing for both controlled and non-controlled medications, as long as you conduct an ‘appropriate prior examination’—which can be via telehealth if it meets the standard of care.

Key California requirements:

• Obtain and document patient consent for telehealth (required by law)
• Check the CURES PDMP database before prescribing any Schedule II–IV medication for the first time, and every 4 months for ongoing therapy
• All prescriptions must be electronic
• Strict Corporate Practice of Medicine rules—only physician-owned entities can provide medical services (impacts how you structure a practice)

California’s Medi-Cal will stop covering GLP-1 medications for weight loss in January 2026, which means more patients will be seeking cash-pay telehealth options.

Texas: Flexible with Oversight

Texas allows telehealth prescribing without requiring an in-person visit, as long as you establish a valid patient relationship via live video (or store-and-forward with audio, if clinically appropriate).

Texas specifics:

• Must check the Texas PMP database for controlled substances (mandatory for opioids, benzos, barbiturates; best practice for all controlled meds including phentermine)
• Required to send a summary to the patient’s primary care provider within 72 hours (if patient consents)
• NPs and PAs need prescriptive authority agreements with physicians—they cannot prescribe independently

Pennsylvania & Illinois: Standard of Care Focus

Both Pennsylvania and Illinois allow telehealth prescribing and generally defer to federal DEA rules for controlled substances. Neither has specific weight-loss prescribing regulations, but both expect:

• Pennsylvania: Check the PA PDMP before first prescription and each time for opioids/benzos. APRNs need collaborative agreements.
• Illinois: APRNs can obtain Full Practice Authority (FPA) after 4,000 hours of experience, allowing independent prescribing including controlled substances. Check the PDMP for Schedule II narcotics each time.

Psychiatrist vs. PMHNP: Scope of Practice Differences

For Psychiatrists (MD/DO):

You have broad prescribing authority. Legally, you can prescribe weight-loss medications—your medical license isn’t restricted to psychiatric drugs only. However, you assume responsibility to practice competently within the standard of care.

If you’re prescribing GLP-1s or phentermine, you should be able to justify it: document the patient’s BMI, rule out contraindications, discuss diet and exercise, and monitor appropriately (blood pressure, heart rate, metabolic parameters). Some psychiatrists pursue additional training or certification in obesity medicine to bolster their credibility, though it’s not legally required.

The reality: You’ll likely encounter weight management issues with patients on antipsychotics (metabolic side effects) or treating binge-eating disorder. Addressing weight holistically can be part of good psychiatric care—just make sure you’re coordinating with the patient’s PCP or endocrinologist when appropriate.

For PMHNPs:

This is trickier. Your scope of practice is defined by your psychiatric mental health training and certification. Prescribing purely for obesity may be viewed by nursing boards as outside your scope, since weight management is typically a primary care or endocrinology domain.

In states requiring physician collaboration (Texas, Pennsylvania, Florida for most NPs), you’d need your collaborating physician to have appropriate expertise in weight management—not just psychiatry. Some states might question whether a psychiatrist can appropriately supervise obesity treatment.

If you’re a PMHNP in a state with full practice authority (California after 2026 if you qualify, Illinois with FPA), you technically could prescribe weight-loss medications independently—but you’d be wise to either get additional training, consult with primary care colleagues, or limit weight management to psychiatric contexts (like treating antipsychotic-induced weight gain).

The practical advice: PMHNPs interested in weight management should consider additional certification (like obesity medicine CME), operate under protocols with physician oversight, or partner with family medicine/internal medicine providers to stay within accepted scope boundaries.

The Economics: What Does Patient Acquisition Really Cost?

Let’s talk business reality. If you’re thinking about launching a weight-loss telehealth service, you need to understand patient acquisition costs—and ignore any marketing that claims you can acquire qualified psychiatric or weight-loss patients for $30-50.

Reality check on DIY marketing:

• Google Ads for mental health and weight loss keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked patient through paid search is $200-400+ when you factor in click costs, testing, optimization, and no-show rates.

• SEO takes 6-12 months of consistent investment (content, technical optimization, link building) before generating meaningful patient flow. Most solo providers don’t have the expertise or budget for this.

• Directory listings (Psychology Today, Zocdoc) charge monthly subscription fees AND you compete with hundreds of providers on the same page. Zocdoc charges per booking ($35-100+), but the total monthly cost including subscription fees adds up quickly.

• Total DIY marketing costs for a new provider typically run $3,000-5,000/month with uncertain results—and that’s IF you have the expertise to execute effectively.

The Klarity Health model:

Instead of gambling on marketing channels, Klarity uses a pay-per-appointment model. You pay a standard listing fee only when a qualified patient books with you. No upfront marketing spend, no monthly subscription fees, no wasted ad spend on clicks that don’t convert.

Key advantages:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients
• Guaranteed ROI vs. the uncertainty of building your own marketing funnel

For most providers—especially those starting out or scaling—a platform that handles patient acquisition removes the financial risk entirely. You can focus on clinical care while the platform manages the expensive, expertise-intensive work of patient acquisition.

The Standard of Care: What Regulators Actually Expect

Regardless of your state, medical boards expect weight-loss prescribers to provide comprehensive care. Here’s what that means practically:

Initial Evaluation

• Thorough medical history (including psychiatric history—medications, eating disorders, mood issues)
• Document current weight, BMI, previous weight-loss attempts
• Screen for contraindications (cardiovascular disease, hyperthyroidism, substance abuse history)
• Appropriate labs if indicated (thyroid function, glucose, lipids)
• Discussion of diet, exercise, and behavioral modifications

Informed Consent

Many states (Florida, California, New Jersey) require documented informed consent specifically for weight-loss treatment. At minimum, you should discuss:

• Expected benefits and realistic outcomes
• Potential side effects and risks
• Alternative treatments
• The importance of lifestyle changes alongside medication
• Cost (especially for cash-pay services)

Ongoing Monitoring

• Follow-ups at least every 3 months (Florida’s requirement; national guidelines often recommend monthly early in treatment)
• Monitor vital signs (blood pressure, heart rate—especially for phentermine)
• Assess efficacy and adjust treatment
• Document continued medical necessity
• Coordinate with the patient’s primary care provider when possible

Red Flags to Avoid

State medical boards have disciplined providers for:

• Prescribing weight-loss medications without adequate evaluation (online questionnaire only)
• No follow-up or monitoring after initial prescription
• Advertising guaranteed results or misleading claims
• Improper delegation to staff or operating outside scope
• Failing to check PDMP databases for controlled substances

Practical Compliance Checklist

Before You Start Prescribing:

☐ Verify you’re licensed in the state where the patient is located
☐ Confirm your state allows telehealth prescribing for the specific medication
☐ Set up PDMP access and e-prescribing in all states where you practice
☐ Create telehealth consent forms and weight-loss informed consent documents
☐ Develop protocols for initial evaluation, monitoring, and follow-up
☐ If you’re an NP or PA, ensure your collaborative agreement explicitly covers weight management
☐ Check if your state requires specific obesity treatment disclosures (like Florida’s Consumer Bill of Rights)

For Each Patient Visit:

☐ Document patient location and verify your licensure there
☐ Obtain telehealth consent (if required in that state)
☐ Conduct thorough evaluation via video (document what you observed)
☐ Check PDMP if prescribing controlled substances (document the query)
☐ Provide weight-loss informed consent and document discussion
☐ E-prescribe (paper prescriptions are banned in many states)
☐ Schedule appropriate follow-up (at least every 3 months for ongoing meds)
☐ Send summary to patient’s PCP if state requires or clinically appropriate

Ongoing:

☐ Stay current on DEA rule changes (permanent telehealth regulations expected)
☐ Monitor state medical board updates for telehealth and obesity treatment rules
☐ Document all patient interactions thoroughly (boards review telehealth records)
☐ Review outcomes and adjust protocols based on patient safety data
☐ Maintain malpractice insurance that covers telehealth and weight management

Frequently Asked Questions

Can psychiatrists legally prescribe Ozempic or Wegovy for weight loss via telehealth?

Yes, in most states. GLP-1 medications are not controlled substances, so they aren’t subject to DEA’s in-person exam requirements. You must conduct an appropriate telehealth evaluation (typically video), document medical necessity (BMI criteria), and follow your state’s telehealth standards. Some states require telehealth patient consent and periodic re-evaluations.

Do I need an in-person visit to prescribe phentermine via telehealth?

It depends on your state. Currently through December 2026, federal DEA rules allow telehealth prescribing of controlled substances without an in-person visit. However, New York state law requires at least one in-person exam before prescribing any controlled substance (with narrow exceptions). Other states like Texas, Florida, California, Pennsylvania, and Illinois currently permit telehealth-only prescribing of phentermine under the federal extension, as long as you meet standard of care requirements.

As a PMHNP, can I prescribe weight-loss medications?

Legally, it’s complicated. Your scope of practice is defined by your psychiatric mental health training. Prescribing purely for obesity may be outside your scope unless you have additional training or certification. In states requiring physician collaboration, you’d need a collaborating physician with appropriate expertise in weight management (not just psychiatry). In states with full practice authority for NPs, you technically could prescribe independently, but professional risk remains if nursing boards view it as outside your competency. Best practice: obtain additional obesity medicine training, collaborate with primary care providers, or limit weight management to psychiatric contexts (like managing medication-induced weight gain).

What happens when the DEA telehealth extension expires in 2026?

The DEA is developing permanent regulations that will likely require special telemedicine registrations for prescribing controlled substances remotely. Proposed rules suggest possible restrictions like requiring the provider and patient to be in the same state, limiting quantities (e.g., 30-day initial supplies), or capping telehealth prescriptions as a percentage of your practice. Psychiatrists may get specific carve-outs for mental health controlled substances (like ADHD stimulants). Until final rules are published, continue following current requirements but plan for potential changes to your practice model.

Do I have to check the prescription drug monitoring program (PDMP) every time?

It varies by state and medication:

• New York: Check PMP within 24 hours before prescribing any Schedule II, III, or IV controlled substance, every time.
• California: Check CURES before first Schedule II–IV prescription, then every 4 months for ongoing therapy.
• Pennsylvania: Check PA PDMP before first prescription of any controlled substance, and each time for opioids and benzodiazepines. Other controlled substances (like stimulants or phentermine) should be checked per clinical judgment.
• Illinois: Check for Schedule II narcotics each time; other controlled substances are recommended but not mandated by law.
• Texas: Mandatory check for opioids, benzodiazepines, barbiturates, and carisoprodol. Phentermine isn’t on the mandatory list, but best practice is to check for all controlled substances.

Can I prescribe weight-loss medications to patients in multiple states via telehealth?

Yes, but you must hold an active medical license in each state where your patients are located when they receive care. There is no federal telehealth license. Some states participate in interstate compacts (Interstate Medical Licensure Compact for physicians, Nurse Licensure Compact for NPs) that streamline the multi-state licensure process, but you still need to apply and maintain licenses in each state. Also verify each state’s specific telehealth prescribing rules—what’s allowed in Texas may be prohibited in New York.

What are the biggest compliance mistakes to avoid?

Based on state medical board enforcement actions:

1. Online questionnaire-only evaluations without real-time video interaction
2. No follow-up after initial prescription (states expect periodic monitoring)
3. Failing to check PDMPs for controlled substances when required
4. Advertising guaranteed results or misleading weight-loss claims
5. Practicing outside your scope (especially NPs prescribing without appropriate collaboration)
6. Inadequate documentation of the telehealth exam and medical necessity
7. Not obtaining required informed consent (telehealth consent, weight-loss consent)
8. Prescribing across state lines without proper licensure

The Bottom Line

Psychiatrists can absolutely prescribe weight-loss medications via telehealth—and there’s real clinical and business opportunity here, especially as more patients seek convenient access to GLP-1 therapies. But the regulatory landscape is complex and changing.

Key principles to follow:

1. Know your state’s specific rules. Generic compliance won’t cut it—Florida, New York, California, and Texas all have different requirements.

2. Document thoroughly. Telehealth records get scrutinized. Your notes should show a comprehensive evaluation, informed consent, monitoring plan, and clinical rationale.

3. Stay within your scope. Psychiatrists practicing competently in obesity medicine is one thing; a PMHNP prescribing outside their training without appropriate collaboration is another.

4. Plan for regulatory changes. The DEA extension expires December 31, 2026. Build flexibility into your practice model.

5. Focus on patient safety, not just revenue. The regulatory backlash against ‘pill mill’ telehealth services is real. Provide comprehensive care, coordinate with PCPs, and follow up consistently.

6. Consider the economics carefully. Building your own patient acquisition funnel is expensive and uncertain. Platforms like Klarity that provide pre-qualified patients on a pay-per-appointment basis remove the financial risk of DIY marketing.

If you’re thinking about adding weight management to your practice—or you’re already prescribing and want to ensure compliance—the key is staying informed, documenting meticulously, and following both the letter and spirit of the law in each state where you practice.

Ready to see qualified weight-loss patients without the marketing headaches? Klarity Health connects licensed psychiatrists and prescribers with patients seeking weight management and mental health care via telehealth. You set your schedule, we handle patient acquisition—you only pay when patients book. Explore joining Klarity’s provider network to grow your practice the smart way.

Sources and References

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (Jan 2, 2026) – https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Medical Director Compliance Consulting – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide’ (2025) – https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

3. Medical Director Compliance Consulting – ‘California Weight Loss Clinic & Telehealth Compliance Guide (2025)’ – https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/

4. Center for Connected Health Policy (CCHP) – ‘State Telehealth Policies for Online Prescribing’ (Updated Nov 21, 2025) – https://www.cchpca.org/topic/online-prescribing/

5. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (Mar 30, 2024) – https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs

6. McDermott Will & Emery – ‘Weight-Loss Programs in Florida: State Law Considerations for GLP-1 Telehealth Providers’ (Sep 29, 2023) – https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/

7. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (2019, accessed 2025) – https://florida.public.law/statutes/fla.stat.456.47

8. Florida Administrative Code 64B8-9.012 – ‘Standards for the Prescription of Drugs to Treat Obesity’ (Effective Aug 8, 2022) – https://regulations.justia.com/states/florida/64/64b8/chapter-64b8-9/section-64b8-9-012/

9. New York Codes, Rules & Regulations Title 10, §80.63 – NY DOH Regulation on Prescribing (Amended May 2025) – https://www.law.cornell.edu/regulations/new-york/10-NYCRR-80.63

10. Fierce Healthcare – ‘Primary care doctors concerned about telehealth GLP-1 boom: survey’ by Heather Landi (Feb 13, 2025) – https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey

11. California Medical Association (CMA) – ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal’ (Dec 2, 2025) – https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal

12. Pennsylvania Department of Health – Prescription Drug Monitoring Program FAQs (2022, accessed 2025) – https://www.pa.gov/agencies/health/programs/opioids/prescribers-and-providers/prescribing-guidelines.html

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated